AKR7L Antibody

Background

Aflatoxin B1 Aldehyde Reductase Member 4 (AKR7L) is an enzyme that belongs to the aldo-keto reductase (AKR) superfamily, which is involved in the detoxification of reactive aldehydes and ketones. AKR7L specifically catalyzes the reduction of aflatoxin B1 dialdehyde, a highly toxic and carcinogenic metabolite produced by aflatoxin B1, into less harmful compounds, thereby reducing its potential to cause DNA damage and cancer. This enzyme is primarily expressed in the liver, where it plays a critical role in protecting against oxidative stress and chemical toxicity. Dysregulation or deficiency of AKR7L has been linked to increased susceptibility to aflatoxin-induced hepatocellular carcinoma and other toxicant-related liver diseases. AKR7L is also involved in the detoxification of endogenous aldehydes generated during lipid peroxidation, highlighting its broader role in maintaining cellular redox balance. Research into AKR7L focuses on its potential as a therapeutic target to enhance detoxification processes and reduce the risk of aflatoxin-related liver cancer.